Myeloproliferative neoplasms (MPNs) are clonal disorders of hematopoietic stem cells characterized by proliferation of 1 or more myeloid lineages. In the revised 2008 World Health Organization (WHO) classification of MPNs, the mutational status of JAK2, a tyrosine kinase involved in intracellular signaling, is an essential part of the diagnostic algorithm. 1 The JAK2 V617F point mutation has been reported in more than 90% of patients with polycythemia vera (PV) and approximately half of patients with primary myelofibrosis (PMF) and essential thrombocythemia (ET). 2-5 JAK2 exon 12 mutations account for a significant number of JAK2 V617F -PV cases. 6, 7 Also included in the WHO classification of myeloid malignancies are myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), which show characteristics of myelodysplastic syndrome (MDS) and MPN. MDS/MPN demonstrates a significant albeit lower frequency of JAK2 mutations (<10%). 2, 8, 9 The clinical course of MPN and MDS/MPN varies markedly within the same diagnostic subtype, and the existing prognostic system is mainly based on peripheral blood parameters and constitutional symptoms. Cytogenetic and molecular aberrations have historically not been a predominant part of the risk stratification system. In particular, the study of cytogenetic abnormalities to stratify disease prognosis in most types of MPN and MDS/MPN is still in its early stages compared with acute myeloid leukemias (AMLs). In contrast, in PMF, investigators have proposed that karyotypic abnormalities provide relevant prognostic information and have suggested a new international prognostic scoring system incorporating cytogenetic risk categorization. [10] [11] [12] In comparison, cytogenetic studies in ET and PV have not yielded consistent prognostic information, even though some common recurrent cytogenetic abnormalities have been identified,
Myeloproliferative neoplasms and myelodysplastic/ myeloproliferative neoplasms are heterogeneous disorders. JAK2 mutation testing and karyotyping are routinely used for diagnosis but have not been incorporated into risk stratification in
). Chromosome 9, chromosome 7, and 20q-were recurrent abnormalities in the JAK2+ group, whereas 13q-and trisomy 21 were common in the JAK2-group. In the JAK2+ group, chromosome 7 and complex cytogenetic abnormalities were associated with excess blasts/blastic transformation (P < .05), whereas no cases with 20q-underwent blastic transformation. Our results suggest that incorporation of JAK2 mutation testing and karyotyping allows for monitoring of disease progression with prognostic and therapeutic implications.
Myeloproliferative neoplasms (MPNs) are clonal disorders of hematopoietic stem cells characterized by proliferation of 1 or more myeloid lineages. In the revised 2008 World Health Organization (WHO) classification of MPNs, the mutational status of JAK2, a tyrosine kinase involved in intracellular signaling, is an essential part of the diagnostic algorithm. 1 The JAK2 V617F point mutation has been reported in more than 90% of patients with polycythemia vera (PV) and approximately half of patients with primary myelofibrosis (PMF) and essential thrombocythemia (ET). [2] [3] [4] [5] JAK2 exon 12 mutations account for a significant number of JAK2 V617F -PV cases. 6, 7 Also included in the WHO classification of myeloid malignancies are myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), which show characteristics of myelodysplastic syndrome (MDS) and MPN. MDS/MPN demonstrates a significant albeit lower frequency of JAK2 mutations (<10%). 2, 8, 9 The clinical course of MPN and MDS/MPN varies markedly within the same diagnostic subtype, and the existing prognostic system is mainly based on peripheral blood parameters and constitutional symptoms. Cytogenetic and molecular aberrations have historically not been a predominant part of the risk stratification system. In particular, the study of cytogenetic abnormalities to stratify disease prognosis in most types of MPN and MDS/MPN is still in its early stages compared with acute myeloid leukemias (AMLs). In contrast, in PMF, investigators have proposed that karyotypic abnormalities provide relevant prognostic information and have suggested a new international prognostic scoring system incorporating cytogenetic risk categorization. [10] [11] [12] In comparison, cytogenetic studies in ET and PV have not yielded consistent prognostic information, even though some common recurrent cytogenetic abnormalities have been identified, including 20q-, trisomy 9, 13q-, trisomy 8, and others. [13] [14] [15] [16] [17] Often, the number of patients in each study is too small for investigators to be certain about a particular genetic abnormality. It is still controversial whether cytogenetic abnormalities should be included in a risk stratification scheme for ET or PV. Furthermore, the prevalence and pattern of cytogenetic abnormalities for JAK2+ vs JAK2-MPN and MDS/MPN have not been established.
The aim of this study was to determine whether cytogenetic data and JAK2 mutation status provide prognostic information by analyzing cytogenetic abnormalities with JAK2 mutational status data and correlating with the pathologic stage in cases of MPN and MDS/MPN, such as myelofibrosis or blastic transformation, from our single institution experience.
Materials and Methods

Cases
The study was approved by the Oregon Health & Science University (OHSU, Portland) Institutional Review Board. The OHSU surgical pathology files and clinical history database were searched for the period from 2005 to 2010 to identify cases of JAK2+ and JAK2-MPNs and MDS/MPNs (with and without cytogenetic data). The diagnoses and subclassifications were made according to WHO diagnostic criteria by using morphologic findings and clinical data. A total of 106 JAK2+ and 73 JAK2-cases were identified. The subclassification of these JAK2+ and JAK2-cases is provided in ❚Table 1❚.
JAK2 Mutational Analysis
Testing for the JAK2 V617F mutation was performed by allele-specific polymerase chain reaction (PCR) on DNA prepared from bone marrow or peripheral blood specimens according to the method of Jones et al. 4 This method uses 1 primer pair to specifically amplify the normal (wild-type) sequence (229-base-pair product) and another primer pair to specifically amplify the mutant sequence (279 base pairs). The PCR products were sized by capillary electrophoresis (QIAxcel analyzer, Qiagen, Valencia, CA), which was routinely able to detect the V617 mutant allele down to a dilution limit (into wild-type DNA) of 0.5%. A 0.5% low mutant-allele burden control was included in each batch run of genotypes, and, if the mutant allele-specific PCR signal of any unknown sample exceeded that of the low-level (0.5%) control, it was interpreted as "positive" for JAK2 V617F .
Cytogenetics
Standard cytogenetic karyotype analysis was performed at the OHSU cytogenetics laboratory at the time of bone marrow biopsy or aspiration on 45 JAK2+ cases and 52 JAK2-cases. The bone marrow specimen was cultured for 24 to 48 hours in complete RPMI 1640 medium (Invitrogen, Carlsbad, CA) with 10% fetal bovine serum (Irvine Scientific, Santa Ana, CA). Cells were harvested and slides prepared according to standard laboratory protocol. Slides were treated with 10% trypsin (Invitrogen) for 40 to 55 seconds followed by Wright stain (Sigma, St Louis, MO) for 2 minutes, 30 seconds. These GTW-banded preparations were analyzed on a Nikon Eclipse E800 microscope (Nikon Instruments, Melville, NY) with Applied Imaging CytoVysion software (Genetix, San Jose, CA). 18 When possible, at least 20 metaphase cells were examined for each case.
Statistics
We assessed the univariate relationship between each of the predictor variables (hemoglobin level, WBC count, platelet count, age, normal cytogenetics, 20q deletion, chromosome 7 abnormalities, chromosome 9 abnormalities, monosomal karyotype, and complex cytogenetic abnormalities [>3 chromosome abnormalities]) with the outcome variable (blastic transformation/excess blasts) for JAK2+ cases by using univariate logistic regression. Then we fit a multivariate logistic regression to the data. All P values were 2-tailed, and statistical significance was set at the level of P less than .05. Analysis was performed using SAS software, version 9.2 (SAS Institute, Cary, NC) ❚Table 2❚. ). As we expected, PV was significantly more frequent in the JAK2+ group and CMML was significantly more frequent in the JAK2-subset.
Results
Comparison of Diagnostic
Cytogenetic Findings in JAK2+ MPN and MDS/MPN
Overall, 45 of 106 JAK2+ cases had cytogenetic data available for review. Diagnostic subclassification and corresponding cytogenetic findings are given in ❚Table 3❚. Cytogenetic abnormalities were identified in 23 (51%) of 45 cases, with frequencies of 25% for CMML (1/4), 40% for ET (2/5), 53% for PV (8/15) , and 60% for PMF (9/15). The occurrence of cytogenetic abnormalities in cases with blastic transformation or excess blasts was significantly higher (12/14 [86%]) than in cases without (11/31 [35%]; P < .05). Recurrent cytogenetic abnormalities in the JAK2+ group included 20q-, chromosome 7 abnormalities (7q-and -7), chromosome 9 abnormalities [trisomy 9 and t(1;9)], chromosome 17 abnormalities (17q-and isochromosome 17q), and chromosome 5 abnormalities (5q-and monosomy 5). The relationship between cytogenetic abnormalities and outcome (blastic transformation/ excess blasts) was analyzed using univariate logistic regression and multivariate analysis and is shown in Table 2 .
In our series, 20q-as the sole cytogenetic abnormality was seen in 4 JAK2+ cases with abnormal cytogenetics, including 1 post-PV MF case, 2 PMF cases, and 1 MPN case; none of these cases underwent blastic transformation, suggesting that 20q-is associated with a better prognosis, although this did not reach statistical significance perhaps owing to the small sample.
Chromosome 9 abnormalities such as trisomy 9 and t(1;9) were seen in 5 cases. Of the 5 cases, 4 (80%) underwent transformation to AML, including 2 post-PV cases with blastic transformation, 1 PMF case with blastic transformation, and 1 CMML case with blastic transformation. For the case of CMML with blastic transformation, the original clone demonstrated trisomy 9 at diagnosis that evolved into a tetraploid chromosome 9 at the time of transformation. For the case of PV with blast phase, the original clone demonstrated trisomy 9, and an additional new deletion of 7q-was seen at the time of blastic transformation.
Three cases demonstrated a monosomal karyotype defined as the presence of 2 distinct autosomal monosomies or a single autosomal monosomy in the presence of other structural abnormalities. PV, 1 case of MDS/MPN, and 1 case of MPN, all of which underwent blastic transformation. By using univariate analysis, we found that chromosome 9 abnormalities and monosomal karyotype were associated with blastic transformation; however, this association was not significant by multivariate analysis, although the number of cases is small.
Chromosome 7 abnormalities (7q-or monosomy 7) were also commonly seen (7/45 cases). In 3 cases, there was a sole chromosome 7 abnormality, 3 cases had an abnormal chromosome 7 with complex cytogenetic abnormalities (>3 chromosome abnormalities), and 1 case had trisomy 9. A total 5 of 7 cases had blastic transformation, including 4 cases of PV, blast phase, and 1 case of MDS/MPN, blast phase. The association of chromosome 7 abnormalities with blastic transformation was statistically significant (P < .05) by univariate and multivariate analyses, indicating this cytogenetic abnormality portends a worse prognosis in JAK2+ cases. Other common cytogenetic abnormalities involved chromosomes 5 and 17. All were associated with complex cytogenetic abnormalities and related to excess blasts or blastic transformation (P < .05). When correlating with stage of the disease, our results indicate that the frequency of cytogenetic abnormalities continuously increased from a nonfibrotic stage to marrow fibrosis and to blastic transformation/excess blasts regardless of JAK2 mutation status ❚Figure 2❚.
Cytogenetic Findings in JAK2-MPN and MDS/MPN
Recurrent chromosomal aberrancies differed between the JAK2+ and JAK2-groups ❚Table 5❚. Cytogenetic abnormalities of chromosomes 5, 7, 9, 12, 17, and 20 were more common in the JAK2+ group, whereas chromosome 13 abnormalities In the present study, the lowest rate of cytogenetic abnormalities was in early stage PV and ET without marrow fibrosis or blastic transformation, 40% to 50% in myelofibrosis, and nearly 90% in blastic transformation/excess blasts. These findings are in accordance with published studies. 12, 35 Our study further highlights that this trend is observed in JAK2+ and JAK2-groups and shows that cytogenetic abnormalities are more frequent in the JAK2+ group than in the JAK2-group (51% vs 27%; P < .05), which has not been reported by other groups using conventional cytogenetic analysis. Only recently, Tefferi et al 36 showed that changes of chromosome copy number were detected more often in JAK2+ ET and PMF cases by using oligonucleotide array comparative genomic hybridization. We demonstrated a greater frequency of blast phase disease in the JAK2+ than in the JAK2-cases (33% vs. 21%). Although the latter was not statistically significant, other studies have shown that JAK2 mutation confers a worse prognosis using hematologic and clinical parameters ❚Table 7❚.
and trisomy 21 were more frequent in the JAK2-group. The 20q-was not identified in cases with blastic transformation (0/5), whereas abnormalities of chromosomes 5, 7, 9, and 17 and complex cytogenetics were unfavorable cytogenetic changes associated with blastic transformation ❚Table 6❚. In 4 cases, a monosomal karyotype was found; 3 of these cases were identified in the JAK2+ group and 1 was identified in the JAK2-group. All cases with a monosomal karyotype were seen in patients with the blast phase of disease.
Discussion
The relationship between JAK2+ and JAK2-subtypes of MPN and molecular mechanisms of disease progression in the 2 subtypes is not clear. Several studies have indicated that a JAK2 mutation is an unfavorable prognostic factor based on hematologic, clinical, and cytogenetic parameters; only a minority of studies reported different observations. 13, 17, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] The aim of our study was to systematically investigate the correlation of JAK2 mutation status with cytogenetic abnormalities and the correlation of cytogenetic abnormalities with the stage of MPN and MDS/MPN. The frequencies and patterns of cytogenetic abnormalities of JAK2+ and JAK2-MPN and MDS/MPN were described and compared to determine whether specific cytogenetic abnormalities are more commonly associated with JAK2 mutational status and whether these cytogenetic abnormalities yield prognostic information.
It is well-established knowledge that MPN and MDS/ MPN disease progression to myelofibrosis and blast phase is correlated with a poor prognosis and shorter overall survival. The reported overall frequency of cytogenetic abnormalities in MPN varies between 3% and 40%. 15, 24 Our cohort showed an overall rate of cytogenetic abnormalities of 38%, which is at the higher end of what has been reported. This variation seems related to the proportion of different stages of MPN and MDS/MPN included in the studies. Studies from mostly outpatient clinics usually report lower rates of abnormal cytogenetics because most patients are in an early phase of their disease in this setting. Our cohort includes a disproportionately larger number of patients with more advanced disease referred to the OHSU hematologic malignancy and bone marrow transplant center. For example, 33% (5/15) of patients with PV and 35% (6/17) with ET were admitted at the stage of post-PV or post-ET marrow fibrosis, and 40% (6/15) of patients with PV and 12% (2/17) with ET were admitted at the stage of excess blasts/blastic transformation. All of the aforementioned numbers are much higher than previously described in the literature, in which 10% to 15% of PV and 1% to 5% of ET cases reportedly evolve to marrow fibrosis 32, 33 ; and fewer than 5% of PV and fewer than 1% of ET 34 cases transform to blast phase. Campbell et al 24 reported a similar observation. Our study also demonstrated that chromosome 9 abnormalities were more often seen in patients with blastic transformation in the JAK2+ group, with a P value less than .05 using univariate analysis compared with the cases without abnormal chromosome 9; however, this difference did not reach statistical significance in multivariate analysis. Sequential cytogenetic follow-up data were available for 2 of our cases with chromosome 9 abnormalities. In one case of PV with blast phase, the original clone demonstrated trisomy 9 already detected This study further stratified JAK2+ MPN and MDS/ MPN cases using cytogenetic data. Chromosome 7 abnormalities were more often seen in cases with a JAK2 mutation and conferred a worse prognosis with a higher rate of blastic transformation (P < .05). To the best of our knowledge, this is a unique observation, not previously reported.
By examining the pattern of cytogenetic abnormalities in JAK2+ and JAK2-MPN and MDS/MPN cases, we showed that chromosome 9 abnormalities and 20q-were also seen with higher frequency in patients with a JAK2 mutation. showed increased hemoglobin level at diagnosis and increased rate of fibrotic transformation Campbell et al, 22 2006 PMF V617F mutation associated with higher neutrophils and WBC counts and worse overall survival Barosi et al, 23 2007 PMF V617F mutation associated with increased risk of splenomegaly and leukemic transformation Wolanskyj et al, 25 2005 ET V617F mutation associated with advanced age, higher hemoglobin level and WBC counts, and transformation to PV but no association with fibrotic/leukemic transformation or inferior survival Tefferi et al, 29 2005
Primary and V617F mutation associated with older age at diagnosis and history of thrombosis or secondary pruritus but no prognostic significance myelofibrosis Tefferi et al, 30 2008 PMF V617F mutation associated with older age, platelet count >100 × 10 3 /μL (100 × 10 9 /L) and low peripheral blast count; V617F mutation not associated with thrombosis, overall survival, or leukemia-free survival; shortened overall and leukemia-free survival in patients with low V617F allele burden Guglielmelli et al, 31 2009 Post-PV MF and All post-PV MF cases had JAK2 V617F mutation compared with 27% of post-ET MF cases; post-PV post-ET MF MF cases had greater JAK2 allele burden; no association between JAK2 and transformation to acute myeloid leukemia ET, essential thrombocythemia; PMF, primary myelofibrosis; PV, polycythemia vera. MPN, including 20q-, 13q-, 12p-, +8 , +9, 7q-/-7, 5q-/-5, and i17. [15] [16] [17] 29, 37, 41, 42 However, correlation of JAK2 mutation status and cytogenetic abnormalities with prognosis and clinical variables is not well established. It has been suggested that V617F-myeloproliferative neoplasms may represent an earlier phase of the same disease, with a subsequent acquisition of the JAK2 mutation. A study by Kralovics et al 44 suggested the existence of "pre-JAK2 alleles." Based on their findings, it has been proposed that the JAK2 mutation is a late event in the evolution of MPN, arising in a background of other chromosomal abnormalities. Our data suggest that certain cytogenetic changes are more prone to JAK2 mutation. Specifically, trisomy 9 and 20q-are more often seen in JAK2+ cases, whereas 13q-is more likely to be seen in JAK2-cases. These findings indicate that JAK2+ and JAK2-MPNs represent 2 independent genetic pathways with distinct patterns of cytogenetic aberrancies that might not overlap.
Our study highlights the combined role of testing for JAK2 mutation and routine karyotyping in monitoring disease progression and stratifying risk in patients with MPN and MDS/MPN. Multicenter studies are needed to develop a cytogenetic-molecular-based risk stratification system for optimal targeted therapy and improved outcome of MPN and MDS/MPN, as already used in AML management. in chronic phase, and an additional new deletion of 7q-was seen at the time of blastic transformation. For another case of CMML with blastic transformation, the original clone demonstrated a trisomy 9 at diagnosis that evolved into a tetraploid chromosome 9 at the time of transformation (Table 3, cases 18 and 45, respectively). The high frequency of chromosome 9 abnormalities detected in blastic transformation suggests that chromosome 9 abnormalities may be more likely associated with a worse prognosis.
In contrast, 13q-and trisomy 21 were more common in the JAK2-group in our series. Several groups have shown 13q-and 20q-to be associated with favorable outcomes in PMF, 2,15,37 but they do not address the relationship to JAK2 mutation status. In addition, abnormalities of chromosomes 5, 7, and 17 were seen only in cases of myelofibrosis and blastic transformation in our study, suggesting these changes may be related to late-stage disease.
There are limited data on JAK2 mutations in mastocytosis reported in the literature, and a recent article described 5 cases of systemic mastocytosis and coexisting PMF, 4 of which harbored a JAK2 mutation. 38 One group showed no mutations in 28 cases of mastocytosis, 4 and Steensma et al 2 demonstrated a JAK2 mutation in 2 of 8 cases of systemic mastocytosis, 1 of which had associated myelofibrosis and CMML. Our study found 2 of 7 SM-AHNMD cases had JAK2 mutations. The variation of JAK2 mutational status in mastocytosis is likely related to underling MPN rather than mastocytosis.
A monosomal karyotype is defined as 2 or more distinct autosomal monosomies or a single autosomal monosomy in the presence of 1 or more structural chromosomal abnormalities and has been shown to be associated with a poor
Clinical Associations
Isolated chromosome 9 abnormalities seen only in MPN; higher frequency of -7 in MDS/MPN; isolated 5q(del), -7, and complex aberrations more common in MDS 13q-and 20q-associated with better prognosis NA Abnormal cytogenetics associated with splenomegaly, tobacco use, venous thrombosis, and anemia but no impact on disease evolution or survival No association with worse outcome NA +8, 12p-associated with inferior survival; survival not adversely affected by 20q-or 13q--7/7q-associated with worse prognosis but did not correlate with leukemic transformation Could not confirm better prognosis in 13q-and 20q-group
